Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does atazanavir cause lipodystrophy?

Brian G Gazzard1, Graeme Moyle

  • 1The Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK.

Journal of HIV Therapy
|July 9, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of Biktarvy (B/F/TAF) on whole-body insulin sensitivity, lipid and endocrine profile in healthy volunteers.

HIV medicine·2026
Same author

Durable efficacy of dolutegravir/rilpivirine switch in subjects with HIV RNA <50 copies/ml and history of K103N mutation.

AIDS (London, England)·2026
Same author

Outcomes in people with HIV who resume or switch to bictegravir/emtricitabine/tenofovir alafenamide following a treatment interruption.

AIDS (London, England)·2025
Same author

Brief Report: Resolution of Neuropsychiatric Adverse Events After Switching to a Doravirine-Based Regimen in the Open-Label Extensions of the DRIVE-AHEAD and DRIVE-FORWARD Trials.

Journal of acquired immune deficiency syndromes (1999)·2025
Same author

Antiretrovirals and Weight Change: Weighing the Evidence.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2024
Same author

Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.

The lancet. HIV·2024
Same journal

Implications of the SILCAAT and ESPRIT trials and the future for HIV immunotherapy.

Journal of HIV therapy·2010
Same journal

A review of the use of activation markers in Africa.

Journal of HIV therapy·2010
Same journal

Lymphocyte activation in HIV-1 infection: time for quality control.

Journal of HIV therapy·2010
Same journal

HIV immunology: what lessons can we learn from recent vaccine trials?

Journal of HIV therapy·2010
Same journal

SILCAAT and ESPRIT: taking stock.

Journal of HIV therapy·2010
Same journal

HIV, atherosclerosis and inflammation: implications for treatment.

Journal of HIV therapy·2010
See all related articles

Atazanavir, an HIV protease inhibitor, does not cause lipid abnormalities. This review explores the implications for future fat redistribution issues in patients.

Area of Science:

  • Pharmacology
  • Virology
  • Clinical Medicine

Background:

  • Atazanavir is a once-daily, non-pepsidic HIV protease inhibitor approved in the UK and USA.
  • A key benefit of Atazanavir is its lack of association with lipid abnormalities.
  • This has led to expectations of no future fat redistribution issues with Atazanavir use.

Purpose of the Study:

  • To explore the implications of Atazanavir's lipid profile.
  • To investigate the potential for fat redistribution abnormalities in patients using Atazanavir.

Main Methods:

  • Literature review of studies on Atazanavir and its metabolic effects.
  • Analysis of clinical data regarding lipid profiles and fat redistribution in HIV patients on Atazanavir.

Related Experiment Videos

Main Results:

  • Atazanavir is associated with a favorable lipid profile compared to other protease inhibitors.
  • Current data suggests a low risk of significant fat redistribution abnormalities.

Conclusions:

  • The absence of lipid abnormalities with Atazanavir supports its favorable metabolic profile.
  • Further long-term studies are warranted to definitively confirm the lack of fat redistribution issues.